Denali Therapeutics Inc (FRA:4DN)

€ 20.31 -0.18 (-0.88%) Market Cap: 2.85 Bil Enterprise Value: 2.09 Bil PE Ratio: 0 PB Ratio: 2.25 GF Score: 54/100

Denali Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Denali Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Denali Therapeutics Inc DNL310 NfL Webinar Transcript
Jun 20, 2023
Denali Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023
Denali Therapeutics Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Ultragenyx Pharmaceutical Inc at Cowen Health Care Conference- Orphan CNS Panel Discussion Transcript
Mar 07, 2023
Denali Therapeutics Inc at 41st Annual J.P. Morgan Healthcare Conference Transcript
Jan 10, 2023
Denali Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022
Denali Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 14, 2022
Denali Therapeutics Inc at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript
Apr 28, 2022
Denali Therapeutics Inc at Stifel CNS Days (Virtual) Transcript
Mar 29, 2022
Denali Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2022
Denali Therapeutics Inc to Highlight ALS and FTD Development Programs Transcript
Oct 06, 2021
Denali Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 13, 2021
Denali Therapeutics Inc at Wedbush PacGrow Healthcare Conference (Virtual) Transcript
Aug 10, 2021
Denali Therapeutics Inc to Present Phase 1/2 Study of DNL310 Presentation Transcript
Jul 25, 2021
Denali Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 09, 2021
Denali Therapeutics Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 01, 2021
Denali Therapeutics Inc at UBS Global Healthcare Virtual Conference Transcript
May 24, 2021
Denali Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2021
Denali Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 14, 2020
Passage Bio Inc, Denali Therapeutics, and Prevail Therapeutics at Citi BioPharma Conference (Virtual) - Panel Transcript
Sep 10, 2020
Denali Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2020
Denali Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 03, 2020
Denali Therapeutics Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 02, 2020
Denali Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 13, 2020
Denali Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 14, 2020
Denali Therapeutics Inc at Morgan Stanley Healthcare Conference Transcript
Sep 11, 2019

Denali Therapeutics Inc at Jefferies Healthcare Conference (Virtual) Transcript

Jun 02, 2020 / 06:30PM GMT

Release Date Price: €24.8 (+1.81%)

Transcript

Michael Jonathan Yee

Jefferies LLC, Research Division - Equity Analyst

Hello, everyone. Welcome to another afternoon session at the 2020 Jefferies Global Healthcare Conference. It's been fantastic so far. And up next with me, I'm really happy to introduce the CEO of Denali Therapeutics, Ryan Watts.

Denali has been on a torrential pace with the pipeline over the last year or 2. And importantly, I think about 2020 as a critically important year for Denali because there's a lot of data reading out this year with all of their programs. So without further ado, Ryan, I'll turn it over to you to give us some update progress and tell us about the milestones coming up.

Ryan J. Watts

Denali Therapeutics Inc. - Co-Founder, President, CEO & Director

Yes. Great. Thanks, Mike. Excellent to be here with all of you remotely at the conference. Looking forward to highlighting some of our science and the progress in terms of the development portfolio. So just a reminder, Denali was founded with one purpose, to defeat degeneration. That goal or purpose extended

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.